Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
Freeline

14.05.2020

Gene Therapy Explained

An animation explaining what gene therapy is, how it has evolved over 50 years and the goal of providing a long-term cure for patients who receive treatment.
Freeline

04.05.2020

Freeline receives Orphan Drug Designation from the FDA for FLT190 for the treatment of Fabry Disease

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for FLT190 for the treatment of Fabry Disease. This comes soon after Freeline announced it had received Orphan Drug Designation for FLT190 from the European Commission, based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency.
Freeline

29.04.2020

Freeline to present data on its AAV gene therapy platform and programmes at the 23rd annual American Society of Gene & Cell Therapy 2020 (3)

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces it will present four abstracts at the 23rd annual American Society of Gene & Cell Therapy (ASGCT) meeting on 12-15 May, 2020. Due to the ongoing COVID-19 pandemic, the organisers, in consultation with relevant authorities, have announced that this year’s ASGCT meeting will be held virtually.
Freeline

23.03.2020

Freeline appoints Julie Krop M.D. as Chief Medical Officer (2)

- Experienced clinical leader with extensive experience in guiding rare disease therapies to registration - London, 23 March, 2020 – Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the appointment of Julie Krop M.D., as Chief Medical Officer (CMO) effective 1 April, 2020.
Freeline

10.03.2020

Freeline receives Orphan Drug Designation from the European Commission for FLT190 for the treatment of Fabry Disease

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that the European Commission (EC) has granted orphan drug designation for FLT190 for the treatment of Fabry Disease, based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).
Freeline

07.02.2020

Freeline Data Update in Haemophilia B

Freeline Data Update at EAHAD conference 7 Feb 2020 – watch our video overview
Freeline

05.02.2020

Freeline to present data on AAV-based gene therapies for Fabry Disease and Gaucher Disease at the 16th annual WORLDSymposium™ 2020

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces it will present data on its gene therapy programmes for Fabry Disease and Gaucher Disease at the 16th annual WORLDSymposium™ in Orlando, Florida, 10–13 February 2020. Freeline data has been selected for two oral presentations and associated posters at the conference.
Freeline

04.02.2020

Freeline appoints Theresa Heggie as Chief Executive

- A biopharma executive with significant experience in commercialisation of treatments for rare diseases joining Freeline after senior roles at leading global rare disease companies including Alnylam and Shire -
Freeline

07.01.2020

Freeline to Present at the 38th Annual J.P. Morgan Healthcare Conference

Freeline to Present at the 38th Annual J.P. Morgan Healthcare Conference
Freeline

10.12.2019

Freeline appoints Julia P Gregory to its Board of Directors

An experienced biopharmaceutical executive with more than 20 years of investment banking experience.

Load More